002422 Share Price Performance
CN¥0
-36.55 (-100.00%)
Price CN¥0
Fair ValueCN¥46.54
Share Pricen/a
Narrative Update • Jul 29
Sichuan Kelun Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
002422 Community Narratives
AN
Fair Value
·Fair Value CN¥46.54 11.2% undervalued intrinsic discount
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value CN¥29 42.5% overvalued intrinsic discount
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value CN¥57 27.5% undervalued intrinsic discount
Rising Middle Class And Aging Populations Will Expand Drug Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
002422: Rising Profit Margins and Cash Dividend Will Drive Positive Outlook
Sichuan Kelun Pharmaceutical pushes a wave of new cancer medicines toward launch, and wider insurance coverage could help those treatments reach far more patients. The upside comes with real strings attached, though: approval decisions, rising launch costs, and intense competition could quickly squeeze profits.Read more
AN
CN¥46.54
11.2% undervalued intrinsic discount
Fair Value
Revenue
11.27% p.a.
Profit Margin
13.25%
Future PE
24.64x
Price in 2029
CN¥56.25
Rising Middle Class And Aging Populations Will Expand Drug Markets
Sichuan Kelun Pharmaceutical is pushing beyond traditional hospital drugs into newer cancer and other advanced treatments, with global partners and faster approvals that could open doors in bigger overseas markets. But tougher pricing rules, rising costs, and reliance on a handful of new launches could quickly squeeze profits if the rollout slows or competition heats up.Read more
AN
CN¥57
27.5% undervalued intrinsic discount
Fair Value
Revenue
17.87% p.a.
Profit Margin
12.9%
Future PE
26.08x
Price in 2029
CN¥68.9
International Regulatory Hurdles And China Pricing Pressure Will Erode Margins
Kelun’s push to grow beyond China could hit a wall as tougher overseas rules, quality scrutiny, and possible patent fights make expansion slower and more expensive than many expect. At the same time, a squeeze on drug prices at home and rising costs to develop new cancer treatments could leave less room for profits, even if its newer medicines gain traction.Read more
AN
CN¥29
42.5% overvalued intrinsic discount
Fair Value
Revenue
8.84% p.a.
Profit Margin
13.35%
Future PE
16.27x
Price in 2029
CN¥35.05
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
002422: Buyback Progress And Refined Assumptions Will Shape Future Returns
Fair Value: CN¥46.54 11.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
002422: Higher Future P/E Assumptions And Completed Buyback Will Support Upside
Fair Value: CN¥57 27.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
002422: Minor Buyback And Lower Future P/E Will Sustain Overvaluation Risk
Fair Value: CN¥29 42.5% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sichuan Kelun Pharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 27, 2026
- 0.99
- 46.45%
- 8.55%
- 14.4%
About 002422
- Founded
- 1996
- Employees
- 20127
- CEO
- WebsiteView website
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
